Poor Sleep Quality May Predict Preclinical Alzheimer’s Disease
Poor Sleep Quality May Predict Preclinical Alzheimer’s Disease
Abstract & Commentary
By Alan Z. Segal, MD, Associate Professor of Clinical Neurology, Weill Cornell Medical College. Dr. Segal reports no financial relationships relevant to this field of study.
Synopsis: Poor sleep quality may predict future Alzheimer’s disease and may play a pathogenic role in its etiology.
Source: Ju YE, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol 2013;70:587-593.
Insomnia is a common complaint among adults and it is well recognized that mental performance can be impaired by poor sleep. Both difficulty falling asleep and trouble staying asleep have been associated with poor cognitive function in cross-sectional elderly cohorts. Sleep impairments leading to excessive daytime sleepiness also have been shown to contribute to cognitive decline. Getting more sleep, however, clearly is not the solution. The quantity of sleep has been shown to have variable effects, with some studies showing a U-shaped relationship between sleep duration and cognition. The Nurse’s Health Study, for instance, suggested that subjects getting 7 hours of sleep had optimal functioning compared to those getting 5 or 9 hours of sleep. Sleep may be further compromised by obstructive sleep apnea, which not only causes oxidative stress, but also disrupts sleep architecture and has been shown to increase the risk of dementia. Snoring itself, in the absence of documented sleep apnea, has shown similar results.
Most prior studies have used subject self-report surveys or sleep diaries to assess variables such as sleep efficiency — defined as the actual time asleep divided by the total time in bed. Formal polysomnography eliminates the imprecision introduced by such patient estimates, but is an artificial environment which itself limits sleep efficiency. Sleep may be measured at home using movement detection (actigraphy) as in the current study or with increasingly available technologies, such as smartphone apps that capitalize on embedded accelerometers and movement detectors to create modestly accurate sleep maps.
In the current study, cognitively normal subjects wore actigraphs for 2 weeks to measure total sleep time and efficiency. Sleep was then correlated with levels of cerebrospinal fluid (CSF) β-amyloid (Aβ) 42. It has been shown that low soluble Aβ42 levels in the CSF are suggestive of insoluble amyloid deposition in brain senile plaques. This decrease in CSF Aβ42 may predate clinical Alzheimer’s disease by 15 years. Low Aβ42 levels have also been correlated with positive findings on amyloid PET imaging.
Among subjects with Aβ42 levels < 500 pg/mL, sleep efficiency was 80.4% compared with those having Aβ42 levels > 500 pg/mL, who had a sleep efficiency of 84.7% (P = 0.04). Frequent napping (3 or more days per week) was also associated with amyloid deposition (31.2% among low Aβ42 subjects compared with 14.7% in the high Aβ42 group, P = 0.03). Total sleep time did not differ between the two groups; however, low Aβ42 subjects spent a longer total time in bed in order to obtain adequate sleep.
Because the relationship between sleep efficiency and Aβ42 could be bidirectional, the investigators also used Aβ42 as an outcome variable and dichotomized sleep into poor (< 75% efficiency) vs good (> 89% efficiency) groups. Subjects with poor sleep had a 5.6-fold increased risk of having low Aβ42 levels compared to subjects with good sleep quality.
As the authors nicely demonstrate in a cyclical flow diagram, these data clearly suggest a two-way street. Aβ accumulation may be disruptive of sleep and conversely impaired sleep may promote Aβ deposition. There are multiple mechanisms by which amyloid plaques may disrupt sleep circuits in the basal forebrain. This pathogenesis is supported by transgenic mouse models prone to amyloid plaques. These animals have markedly impaired sleep-wake cycles. Interestingly, when such mice are immunized with Aβ, preventing plaque formation, sleep architecture is restored. Because Aβ is secreted during active neuronal activity, the investigators further hypothesize that prolonged wakefulness results in a higher concentration of amyloid and therefore an increased plaque burden.
Multiple other behavioral factors that impair sleep in the elderly may further amplify the relationship between poor sleep and Aβ. Depression, schedule changes related to retirement (due to cognitive decline or merely due to age), lack of exercise, and institutionalization (impairing regular light exposure) all may potentially contribute to Aβ deposition. As the authors note, however, Aβ secretion also may have a strong circadian influence. This would vary independent of the subject’s sleep-wake state.
These data confirm that poor sleep efficiency may play a pathogenic role in Alzheimer’s disease. This study has important strengths in its use of actigraphy to quantify sleep and also its use of Aβ42 as a biomarker of Alzheimer’s disease risk in place of psychometric data. Of note, these subjects all underwent exhaustive neuropsychiatric testing, confirming them to all be normal. Aβ42 in a cognitively normal person, however, is not equivalent to a future diagnosis of Alzheimer’s disease. Low CSF levels of Aβ42 may not consistently correlate with pathologically confirmed amyloid plaques, and these plaques may not be uniformly predictive of Alzheimer’s disease. As the authors observe, the use of amyloid imaging and the inclusion of individuals with elevated CSF tau, planned in future studies, could further strengthen the connection between sleep disruption and preclinical Alzheimer’s disease.
Despite these limitations, it is clear that addressing reversible sleep disorders, such as obstructive sleep apnea, may be an important step toward addressing Alzheimer’s disease in its earliest stages. Sleep disorders, including sundowning, excess daytime napping, and insomnia occur in up to 40% of patients with Alzheimer’s disease. Although these phenomena may be the consequence of Alzheimer’s disease, they might also mark a population of people for whom Alzheimer’s disease is in the future and might be prevented.Poor sleep quality may predict future Alzheimers disease and may play a pathogenic role in its etiology.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.